GSK-induced pharmaceutical market storm

Since the beginning of June, GlaxoSmithKline has been reported anonymously, and salespeople have fallen into widespread bribery doctor scandals. Subsequently, police in Beijing, Shanghai and Changsha jointly raided the offices of GlaxoSmithKline and took relevant senior executives to assist in the investigation. For a time, the bribery of foreign drug companies and their sales representatives has become increasingly fierce. This is the first time that the Chinese public security department has filed a case investigation statement for a pharmaceutical company, partially restoring GSK’s complicated case, and will also “direct bribery” and “ "Under the sponsorship project" and other unspoken rules of the industry. Despite drug allegations, the U.S. Department of Justice also submitted evidence that GlaxoSmithKline was suspected of commercial bribery. They disguised cash bribes as consulting fees, high-cost meals, weekend leisure activities, and luxury entertainment activities.

As a large multinational pharmaceutical company, in recent years, GlaxoSmithKline (China) Investment Co., Ltd. has been operating in China. To achieve the purpose of opening up drug sales channels and increasing drug sales prices, it has used direct channels such as travel agencies to provide bribes or sponsorship projects. We paid bribes to individual government officials, a handful of pharmaceutical industry associations and foundations, hospitals, and doctors. At the same time, the company has also used false taxation of special value-added tax invoices, issued false invoices through travel agents, or falsely opened ordinary invoices for cash withdrawals and other illegal criminal activities.

However, what we can generally observe is that foreign companies emphasize academic marketing, which is to share the academic advantages of foreign companies with doctors to impress doctors and allow them to use drugs from foreign companies. However, this alone is not enough. Foreign pharmaceutical companies Basically, they will establish a solid relationship with doctors and pharmacy directors. They must also talk about human factors. Not to mention, competition is fierce and the hospital is fixed. This is also the current market approach commonly used in foreign companies. It works with a number of institutions and institutions to better promote our products.

However, the huge expenses incurred by these foreign companies bribing public relations officials eventually transferred to the head of the patient. A box of drugs costing 70 yuan can be sold for 700 yuan. On the one hand, the burden on patients is greatly aggravated. On the one hand, it seriously threatens domestic drugs. The market competition of enterprises is a problem that we cannot ignore in the reform of the medical and health services. With the disclosure of GlaxoSmithKline China, Pfizer, Novartis and other international pharmaceutical giants have also been investigated. An anti-bribery storm in the pharmaceutical market is intensifying.